CSTL vs. CELC, FLGT, CDNA, SERA, VRDN, GTH, BDSX, PSNL, RNLX, and XGN
Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Celcuity (CELC), Fulgent Genetics (FLGT), CareDx (CDNA), Sera Prognostics (SERA), Viridian Therapeutics (VRDN), Genetron (GTH), Biodesix (BDSX), Personalis (PSNL), Renalytix (RNLX), and Exagen (XGN).
Castle Biosciences (NASDAQ:CSTL) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
In the previous week, Castle Biosciences had 5 more articles in the media than Celcuity. MarketBeat recorded 5 mentions for Castle Biosciences and 0 mentions for Celcuity. Castle Biosciences' average media sentiment score of 0.98 beat Celcuity's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the media.
Castle Biosciences presently has a consensus price target of $31.00, indicating a potential upside of 59.38%. Celcuity has a consensus price target of $29.00, indicating a potential upside of 79.79%. Given Celcuity's higher probable upside, analysts clearly believe Celcuity is more favorable than Castle Biosciences.
Celcuity has a net margin of 0.00% compared to Castle Biosciences' net margin of -26.15%. Castle Biosciences' return on equity of -14.92% beat Celcuity's return on equity.
Celcuity received 243 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 66.60% of users gave Celcuity an outperform vote while only 62.02% of users gave Castle Biosciences an outperform vote.
Castle Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
Castle Biosciences has higher revenue and earnings than Celcuity. Castle Biosciences is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.
92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 7.7% of Castle Biosciences shares are held by insiders. Comparatively, 24.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Castle Biosciences beats Celcuity on 9 of the 16 factors compared between the two stocks.
Get Castle Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Castle Biosciences Competitors List
Related Companies and Tools
